1 enrolling by invitation, 1 recruiting. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Yoon Jun Kim: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE) - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | Yoon Jun Kim | 24 | 2025-04-18 | 2025-05-14 |
| Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy GODEX, Placebo - Non-Alcoholic Fatty Liver Disease | Phase 3 | Enrolling by invitation | Yoon Jun Kim | 196 | 2023-09-25 | 2023-12-01 |
Carcinoma, Hepatocellular (1) · Non-alcoholic Fatty Liver Disease (1)
durvalumab (1) · tremelimumab (1)
South Korea (2)